Weekly case challenge

Dr. Janet Serle discusses the newest IOP-lowering glaucoma medications, including latanoprostene bunod or LBN, netarsudil, fixed-dose combination netarsudil/latanoprost, and the bimatoprost implant.

In this video, Dr. Angelo Tanna discusses what medication to add for a patient who needs a second medication to control intraocular pressure (IOP). He shares findings from a meta-analysis of randomized clinical trials assessing the IOP-lowering efficacy of alpha 2 adrenergic agonists, beta blockers, and carbonic anhydrase inhibitors, when added to a prostaglandin analog.

Recommendations distilled from the PPPs for the diagnosis and management of primary open-angle glaucoma, primary open-angle glaucoma suspect, and primary angle-closure disease

In this presentation from the AGS 2020, Dr. Garway-Heath discusses visual field outcomes from the UKGTS trial testing the prostaglandin analogue latanoprost for open-angle glaucoma.

In this webinar, Drs. Patel, Rhodes, Chen, and Lind provide updates on glaucoma to help comprehensive ophthalmologists.

This learning plan, based on IRIS Registry measure IRIS44: Visual Field Progression in Glaucoma, reviews tools to assess the risk of glaucoma progression and the factors to consider when deciding stepwise treatment.

This study assessed the clinical efficacy and safety of primary selective laser trabeculoplasty (SLT) for open-angle glaucoma (OAG) and ocular hypertension.

This presentation from AGS 2019 is a debate among an expert panel on how to treat various cases on glaucoma, the premise being that the physician should limit outside influences that might stop them from providing the same type of care for their patients that they would for a family member.